Positive News SentimentPositive NewsNASDAQ:JBIO Jade Biosciences (JBIO) Stock Price, News & Analysis $19.75 -0.25 (-1.25%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$19.76 +0.01 (+0.05%) As of 07/31/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Jade Biosciences Stock (NASDAQ:JBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jade Biosciences alerts:Sign Up Key Stats Today's Range$18.64▼$20.0450-Day Range$14.98▼$22.5352-Week Range$6.67▼$28.00Volume600,330 shsAverage Volume862,067 shsMarket Capitalization$974.86 millionP/E RatioN/ADividend YieldN/APrice Target$51.57Consensus RatingModerate Buy Company Overview Jade Biosciences, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments. The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation. Preclinical studies have demonstrated promising activity in models of atopic dermatitis, psoriasis‐associated itch and other dermatologic conditions, supporting the progression of these candidates into human trials. Jade Biosciences’ pipeline strategy includes both topical and systemic formulations to broaden the therapeutic scope across multiple indications. Founded in the mid‐2010s and incorporated in Delaware, Jade Biosciences maintains its headquarters in New Haven, Connecticut. The company’s management team draws on experience from established pharmaceutical and biotechnology organizations, combining expertise in medicinal chemistry, dermatology and clinical development. Listed on the Nasdaq under the ticker JBIO, Jade Biosciences is working to advance its pipeline through clinical milestones while preparing for potential partnerships and regulatory filings in the United States and other key markets. AI Generated. May Contain Errors. Read More Jade Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreJBIO MarketRank™: Jade Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 320th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingJade Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialJade Biosciences has a consensus price target of $51.57, representing about 161.1% upside from its current price of $19.75.Amount of Analyst CoverageJade Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jade Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Jade Biosciences are expected to decrease in the coming year, from ($2.54) to ($2.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jade Biosciences is -9.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jade Biosciences is -9.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJade Biosciences has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted19.82% of the float of Jade Biosciences has been sold short.Short Interest Ratio / Days to CoverJade Biosciences has a short interest ratio ("days to cover") of 7.16.Change versus previous monthShort interest in Jade Biosciences has recently decreased by 7.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJade Biosciences does not currently pay a dividend.Dividend GrowthJade Biosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment1.74 News SentimentJade Biosciences has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Jade Biosciences this week, compared to 3 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jade Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders23.06% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsJade Biosciences has minimal institutional ownership at this time.Read more about Jade Biosciences' insider trading history. Receive JBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JBIO Stock News HeadlinesJade Biosciences Stock Short Interest Report | NASDAQ:JBIO | BenzingaJuly 20, 2026 | benzinga.comIs Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?June 30, 2026 | finance.yahoo.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.August 2 at 1:00 AM | Porter & Company (Ad)Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsJune 26, 2026 | globenewswire.comJade Biosciences Shareholders Approve Governance and Audit MeasuresJune 11, 2026 | tipranks.comJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesJune 5, 2026 | markets.businessinsider.comJade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease TherapiesJune 5, 2026 | quiverquant.comQJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesJune 5, 2026 | globenewswire.comSee More Headlines JBIO Stock Analysis - Frequently Asked Questions How have JBIO shares performed this year? Jade Biosciences' stock was trading at $15.43 at the start of the year. Since then, JBIO shares have increased by 28.0% and is now trading at $19.75. How were Jade Biosciences' earnings last quarter? Jade Biosciences, Inc. (NASDAQ:JBIO) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.05. How do I buy shares of Jade Biosciences? Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today8/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 JBIO's financial health is in the Green zone, according to TradeSmith. JBIO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:JBIO Previous SymbolNASDAQ:JBIO CIK1798749 WebN/A Phone(617) 443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Jade Biosciences$51.57 High Price Target$74.00 Low Price Target$40.00 Potential Upside/Downside+161.1%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.34% Return on Assets-47.32% Debt Debt-to-Equity RatioN/A Current Ratio14.29 Quick Ratio14.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.74 per share Price / Book2.93Miscellaneous Outstanding Shares49,360,000Free Float37,978,000Market Cap$974.86 million OptionableN/A Beta1.43 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:JBIO) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersOne signature away. Expected within months.On May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...Behind the Markets | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredA New Gold Era Is Coming - Here's How to Help Protect Your Retirement NowWashington insiders are quietly talking about a coordinated move to revalue gold—and with the national debt ap...Preserve Gold | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredElon’s S-1 Master Plan Could Rewrite the Rules of AIA researcher who has advised Goldman Sachs, JPMorgan Chase, BlackRock, and Fidelity flew to Starbase after spo...Altimetry | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jade Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jade Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
